The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Over The 2026–2030 Period?
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size has experienced rapid expansion in recent years. This market is projected to expand from $1.06 billion in 2025 to $1.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.6%. Factors contributing to this historical growth include broader coverage of cervical cancer screening initiatives, the increasing integration of molecular diagnostics in gynecological practices, heightened public understanding of high-risk HPV infection dangers, the widespread availability of automated PCR systems, and the proliferation of centralized diagnostic facilities.
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size is projected to experience substantial expansion in the coming years. It is anticipated to reach $2.12 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. This anticipated growth during the forecast period stems from factors such as a greater emphasis on primary hpv screening, a rising need for highly specific cancer risk stratification, the broadening of population-based screening initiatives, the incorporation of digital pathology and reporting systems, and increased capital directed towards precision diagnostics. Key developments expected within this period involve the increasing uptake of mrna-based primary cervical screening assays, the wider implementation of fully automated molecular testing platforms, the growing integration of genotype-specific reflex testing, the development of more precise screening algorithms, and an intensified focus on identifying clinically actionable hpv.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33060&type=smp
Which Major Factors Are Driving The Expansion Of The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
The rising incidence of cervical cancer is anticipated to propel the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market in the future. This malignant condition, which develops in the cells of the cervix, is primarily caused by persistent infection with high-risk human papillomavirus types and represents a significant contributor to cancer-related illness and fatalities among women globally. The increasing prevalence of cervical cancer is growing due to insufficient cervical screening participation, leading to delayed identification and subsequent progression of persistent human papillomavirus infections into cancer. Cervical human papillomavirus messenger ribonucleic acid testing supports the identification of active high-risk human papillomavirus infections, thereby improving risk stratification and facilitating timely interventions to reduce cervical cancer progression. For example, in December 2025, according to Cancer Australia, an Australia-based Government Agency, 265 deaths from cervical cancer occurred in australia in 2023, while an estimated 254 deaths from cervical cancer are projected for 2025. Consequently, the expanding prevalence of cervical cancer is driving the growth of the cervical human papillomavirus messenger ribonucleic acid testing market.
How Is The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Segmented Across Key Categories?
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market covered in this report is segmented –
1) By Product Type: Assay Kits; Instruments; Reagents And Consumables
2) By Application: Cervical Cancer Screening; Research; Other Applications
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
Subsegments:
1) By Assay Kits: Messenger Ribonucleic Acid Detection Kits; Multiplex Testing Kits; High Risk Genotype Specific Kits; Screening And Diagnostic Kits
2) By Instruments: Real Time Polymerase Chain Reaction Systems; Automated Molecular Analyzers; Sample Preparation Systems; Nucleic Acid Extraction Instruments
3) By Reagents And Consumables: Primers And Probes; Enzymes And Buffers; Controls And Standards; Extraction And Purification Consumables
Which Upcoming Trends Are Expected To Influence The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
Leading companies in the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are prioritizing the development of technological advancements, such as multiplex real-time PCR innovations. Their goal is to achieve a competitive advantage by enhancing diagnostic accuracy, enabling the simultaneous detection of E6/E7 mRNA and high-risk HPV genotyping, minimizing false positives, reducing testing expenses, and expanding market adoption. Multiplex real-time PCR innovations refer to the capability to concurrently identify and quantify multiple HPV E6/E7 mRNA targets and high-risk genotypes within a single PCR reaction, thereby improving the accuracy, efficiency, and clinical relevance of cervical HPV testing. For instance, in July 2024, Medicon Hellas S.A., a diagnostics company based in Greece, launched a multiplex real time pcr kit for hpv e6/e7 mrna genotyping, serving as the exclusive distributor for uni-medica in greece and cyprus. The kit is compatible with multiple pcr instruments like bio-rad cfx96 and hongshi slan-96 series for fluorochrome analysis with ct values, can be applied to diverse samples including semen, urine, and anal swabs beyond cytology, and carries CE-IVD marking, providing results in 2.5 hours.
Who Are The Top Companies Competing In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.
Read the full cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report here:
Which Region Is Expected To Experience The Fastest Growth In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
North America was the largest region in the cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33060&type=smp
Browse Through More Reports Similar to the Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market 2026, By The Business Research Company
Human Papillomavirus Hpv Vaccine Market Report 2026
Hpv Testing And Pap Test Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report
Hpv Associated Disorders Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model